3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Drug News -

GSK to stop paying doctors to promote drugs: NY Times

Drug NewsDec 17, 13

GSK to stop paying doctors to promote drugs

GlaxoSmithKline Plc will stop paying doctors to promote its products, Chief Executive Andrew Witty said in an interview with the New York Times, in a move that could be a first for a major drug company.

GSK will also stop tying compensation of sales representatives to the number of prescriptions doctors write, the NY Times said. (link.reuters.com/kac55v)

The company’s decision comes at a time when GSK faces allegations of illegal payments to Chinese doctors and officials.

Chinese police have accused GSK of funneling up to 3 billion yuan ($494 million) to travel agencies to facilitate bribes to boost its drug sales. The accusations are the most serious against a multinational in China in years.

However, in the interview Witty said that the proposed changes were unrelated to the investigation in China, and are part of a years-long effort “to try and make sure we stay in step with how the world is changing.”

Witty declined to comment to the newspaper on the Chinese investigation because he said it was still underway.

GlaxoSmithKline could not immediately be reached for comment by Reuters outside of business hours. ($1 = 6.0715 Chinese yuan)

(Reporting by Sakthi Prasad and Aman Shah in Bangalore; Editing by Supriya Kurane)



Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Gates Foundation awards Notre Dame $23 million for malaria, dengue studies
  Cancer drug protects against diabetes
  Malaria drug target raises hopes for new treatments


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site